Tardive akathisia related to the anti-hypertensive agent Sevikar-a case report

• Main Authors: Men-Ting Hsieh (Author), Pao-Yen Lin (Author), Chia-Jen Tsai (Author), Chiung-Chih Chang (Author), Yu Lee (Author)
• Format: Book
• Published: BMC, 2017-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.1186/s40360-017-0148-3; 2050-6511
• Keywords: Sevikar; Anti-hypertensive agent; Tardive akathisia; Amlodipine; Calcium-channel blocker; Olmesartan; Therapeutics. Pharmacology; RM1-950; Toxicology. Poisons; RA1190-1270
• Source: BMC Pharmacology and Toxicology, Vol 18, Iss 1, Pp 1-3 (2017)

Abstract Background Tardive akathisia (TA) is a subtype of tardive syndrome, and its etiology is still uncertain. Sevikar is an anti-hypertensive agent containing both amlodipine and olmesartan, and has never been reported to have an adverse reaction in patients with tardive syndrome. Case presentation A 57-year-old woman who took Sevikar for hypertension for 10 years developed TA one and a half years before receiving any psychiatric treatment. After switching from Sevikar to bisoprolol, she reported obvious improvement in her akathisia. Conclusions It is noteworthy that her TA developed before receiving any antidepressant medication, and that her TA improved after discontinuation of Sevikar. In light of these pharmacodynamic properties, it is therefore concluded that use of amlodipine and olmesartan might have caused TA in this patient. We reported this rare case to remind clinicians to be aware of possible akathisia when using amlodipine and olmesartan in combination as anti-hypertensive agents.